Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2015
May 2015, Vol 6, No 4
May 2015, Vol 6, No 4
Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting
By
Loretta Fala
Drug Updates
May 2015, Vol 6, No 4
One of the most fear-inducing side effects of chemotherapy is nausea and vomiting. Without appropriate antiemetic prophylaxis, 70% to 80% of all patients with cancer who receive chemotherapy experience nausea and/or vomiting. Consequently, preventing and managing chemotherapyinduced nausea and vomiting (CINV) is a crucial part of care planning for patients with cancer.
Read Article
CancerLinQ Moves to Its Patient Data-Gathering Clinical Phase
By
Rosemary Frei, MSc
Oncology
May 2015, Vol 6, No 4
The American Society of Clinical Oncology (ASCO) and a German company called SAP are launching the clinical phase of ASCO’s big-data initiative—CancerLinQ. This clinical phase is focused on gathering and analyzing data from the 97% of US patients with cancer who do not participate in clinical trials.
Read Article
Revised Survivorship Care Plan Template Reduces Time and Resource Commitments
By
Charles Bankhead
Survivorship
,
Policies & Guidelines
May 2015, Vol 6, No 4
A revised survivorship care plan template addresses obstacles that have limited the use of survivorship plans in clinical practice, suggested an American Society of Clinical Oncology (ASCO) expert panel headed by Deborah K. Mayer, PhD, MSN, RN, Professor of Nursing and Director of Survivorship Care, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill.
Read Article
Health Plan Cost-Savings with Netupitant/Palonosetron for the Prevention of CINV
By
Laura Morgan
Economics & Value
,
Economics of Cancer Care
May 2015, Vol 6, No 4
San Diego, CA—According to the National Comprehensive Cancer Network guidelines for the prevention of chemotherapy-induced nausea and vomiting (CINV), highly and moderately emetogenic chemotherapy should be managed with a 5-HT3 receptor antagonist, an NK1 receptor antagonist, and dexamethasone (Decadron).
Read Article
Real-World Treatment Patterns of Axitinib for Advanced Renal-Cell Carcinoma
By
Laura Morgan
Economics & Value
,
Economics of Cancer Care
May 2015, Vol 6, No 4
San Diego, CA—Approved in 2012 by the FDA, axitinib (Inlyta) is indicated for the treatment of patients with advanced renal-cell carcinoma (RCC) whose disease had failed 1 previous systemic therapy. The approval of axitinib was based on the safety and efficacy data from clinical trials, which are often limited in their patient population and short-term analysis.
Read Article
Substantial Costs Associated with Systemic Therapy After Ipilimumab in Patients with Advanced Melanoma
By
Laura Morgan
Economics & Value
,
Economics of Cancer Care
May 2015, Vol 6, No 4
San Diego, CA—The healthcare costs of patients with advanced melanoma after ipilimumab (Yervoy) therapy are significant, according to recent study findings presented at the 2015 Academy of Managed Care Pharmacy annual meeting.
Read Article
Medicare’s Sustainable Growth Rate Repeal Met with Relief
By
Laura Morgan
Economics & Value
,
Economics of Cancer Care
May 2015, Vol 6, No 4
The April 14, 2015, repeal of the sustainable growth rate (SGR) formula for physician payments under Medicare is being welcomed by the healthcare community, including the American Society of Clinical Oncology (ASCO). The 392 to 37 vote to pass H.R. 2, called the Medicare Access and Children’s Health Insurance Program Reauthorization Act of 2015, came just in time to avoid the 21% cut in Medicare fees that would have come into effect after the most recent SGR patch expired on March 31, 2015.
Read Article
US Oncologists Favor Establishment of NICE-Like Body to Determine Medicare Cancer Drugs Reimbursement
By
Rosemary Frei, MSc
Economics & Value
,
Economics of Cancer Care
May 2015, Vol 6, No 4
Read Article
In the Literature - May 2015
In the Literature
May 2015, Vol 6, No 4
Read Article
Pathways Have the Potential to Deliver Personalized Medicine
By
Wayne Kuznar
Pathways
May 2015, Vol 6, No 4
Washington, DC—The institution of cancer treatment pathways is not incompatible with personalized medicine, but rather it has the potential to offer access to a rapid learning system that can promote personalized therapy, said Michael Kolodziej, MD, National Medical Director, Oncology Solutions, Aetna, at the Fifth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
Page 1 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma